MF59
Squalene-based adjuvant
MF59 is an immunologic adjuvant developed using squalene. It is Novartis's proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory T cells.
MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine. MF59 is used as an adjuvant in Canada, Europe and the United States. MF59 was developed in the 1990s by researchers at Chiron Corporation, a Novartis heritage company, acquired by Novartis in 2006.
Sources and credits
This article is adapted from the Wikipedia article “MF59”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.